Loading clinical trials...
Loading clinical trials...
Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia
Conditions
Interventions
Alirocumab
Lipid-Modifying Therapy (LMT)
Locations
177
United States
Investigational Site Number 840321
Huntsville, Alabama, United States
Investigational Site Number 840341
Tempe, Arizona, United States
Investigational Site Number 840334
Bell Gardens, California, United States
Investigational Site Number 840319
Fountain Valley, California, United States
Investigational Site Number 840336
Los Angeles, California, United States
Investigational Site Number 840339
Mission Viejo, California, United States
Start Date
December 17, 2013
Primary Completion Date
June 30, 2017
Completion Date
June 30, 2017
Last Updated
July 24, 2018
NCT07473960
NCT06568601
NCT00353782
NCT07037771
NCT07489209
NCT07058077
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions